Not exact matches
Rep. Chris Collins — who is facing an Office of Congressional Ethics investigation into his
investment in an obscure Australian biotech firm — walked off the House floor late yesterday afternoon, cellphone in hand, apparently talking about yet another stock trade involving that same company: Innate
Immunotherapeutics.
The ethics office — an independent, nonpartisan entity charged with reviewing allegations of misconduct against members, officers and staff — is concentrating on his
investments in Innate
Immunotherapeutics.
Smierciak said he did not plan to make an issue of the fact that Collins is the subject of an Office of Congressional Ethics investigation in connection with his
investment in Innate
Immunotherapeutics, an Australian biotech firm that he touted for years.
In May, The News reported that the Office of Congressional Ethics is probing his
investment in an obscure Australian biotech firm called Innate
Immunotherapeutics.